Evaluation of response to neoadjuvant chemotherapy in technically unresectable moderately advanced oral cavity cancers.

Publisher: Medknow Publications Country of Publication: India NLM ID: 101249598 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1998-4138 (Electronic) Linking ISSN: 19984138 NLM ISO Abbreviation: J Cancer Res Ther Subsets: MEDLINE

Original Publication: Mumbai, India : Medknow Publications

Mouth Neoplasms*/drug therapy ; Mouth Neoplasms*/pathology ; Mouth Neoplasms*/surgery ; Neoadjuvant Therapy*/methods ; Antineoplastic Combined Chemotherapy Protocols*/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols*/adverse effects; Humans ; Middle Aged ; Male ; Female ; Aged ; Adult ; Treatment Outcome ; Prospective Studies ; Neoplasm Staging ; Prognosis

Background: Moderately advanced and technically unresectable oral cavity cancers have a poor prognosis. Neoadjuvant chemotherapy might be beneficial in such patients by reducing tumour bulk and allowing definitive surgery.
Aim: To evaluate the response of neoadjuvant chemotherapy in moderately advanced technically unresectable oral cavity cancers.
Methodology: Prospective observational study - secondary data analysis of patients with moderately advanced oral cavity cancer, which were treated with neoadjuvant chemotherapy (NACT) during the period November 2014-April 2016. Data was analysed for information on patient characteristics, chemotherapy received, toxicity, clinical response rates, local treatment offered and pathological response rates. The statistical analysis was performed with SPSS version 20.
Results: 30 patients, with a median age of 52 years were analyzed. Buccal mucosa was the most common sub site (50%). Three drug regimen was utilized in all patients. Resectability was achieved in 14 patients (46.67%). Febrile neutropenia was seen in 3 patients (10%). The overall response rate was 31%.
Conclusion: NACT was effective in converting moderately advanced technically unresectable oral cavity cancers to operable disease in approximately 47% of patients. Post NACT, there is significant association between clinical and pathological findings of response rates. There is no increase in surgical complication rates following NACT.
(Copyright © 2024 Copyright: © 2024 Journal of Cancer Research and Therapeutics.)

Coelho KR. Challenges of the oral cancer burden in India. J Cancer Epidemiol 2012 2012;701932.
Kulkarni MR. Head and neck cancer burden in India. Int J Head Neck Surg 2013; 4:29–35.
Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, et al. Head and neck cancers, version 1.2015. J Natl Compr Canc Netw 2015; 13:847–55.
Patil VM, Noronha V, Joshi A, Muddu VK, Gulia S, Bhosale B, et al. Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: Does it make a difference?. Indian J Cancer 2013; 50:1–8.
Kirkwood JM, Miller D, Weichselbaum R, Pitman SW. Predefinitive and postdefinitive chemotherapy for locally advanced squamous carcinoma of the head and neck. Laryngoscope 1979; 89:573–81.
Lustig RA, DeMare PA, Kramer S. Adjuvant methotrexate in the radiotherapeutic management of advanced tumors of the head and neck. Cancer 1976; 37:2703–8.
Jacobs C. Adjuvant and neoadjuvant treatment of head and neck cancers. Semin Oncol 1991; 18:504–14.
Jacobs C, Pinto H. Adjuvant and neoadjuvant treatment of head and neck cancers: The next chapter. Semin Oncol 1995; 22:540–52.
Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, et al. Surgical outcome of T4a and resected T4b oral cavity cancer. Cancer 2006; 107:337–44.
Pignon J, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000; 355:949–55.
Pignon JP, le Maître A, Maillard E, Bourhis J MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92:4–14.
Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357:1705–15.
Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357:1695–704.
Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: Long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 2011; 12:153–9.
Eisenhauer E, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228–47.
Muwonge R, Ramadas K, Sankila R, Thara S, Thomas G, Vinoda J, et al. Role of tobacco smoking, chewing and alcohol drinking in the risk of oral cancer in Trivandrum, India: A nested case-control design using incident cancer cases. Oral Oncol 2008; 44:446–54.
Sankaranarayanan R. Oral cancer in India: An epidemiologic and clinical review. Oral Surg Oral Med Oral Pathol 1990; 69:325–30.
Posner MR. Paradigm shift in the treatment of head and neck cancer: The role of neoadjuvant chemotherapy. Oncologist 2005; 10 Suppl 3: 11–9.
Colevas AD, Busse PM, Norris CM, Fried M, Tishler RB, Poulin M, et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: A phase I/II trial. J Clin Oncol 1998; 16:1331–9.
Colevas A, Norris CM, Tishler RB, Fried MP, Gomolin HI, Amrein P, et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 1999; 17:3503–11.
Colevas A, Norris CM, Tishler RB, Lamb CC, Fried MP, Goguen LA, et al. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am J Clin Oncol 2002; 25:153–9.
Posner MR, Glisson B, Frenette G, Al-Sarraf M, Colevas AD, Norris CM, et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2001; 19:1096–104.
Janinis J, Papadakou M, Panagos G, Panousaki A, Georgoulias V, Hatzidaki D, et al. Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol 2001; 24:227–31.
Schrijvers D, Van Herpen C, Kerger J, Joosens E, Van Laer C, Awada A, et al. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I–II feasibility study. Ann Oncol 2004; 15:638–45.
Tsukuda M, Mikami Y, Tanigaki Y, Katori H, Horiuchi C, Ikeda Y, et al. Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck. Int J Clin Oncol 2004; 9:161–6.
Watanabe A, Taniguchi M, Sasaki S. Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: A modified regimen for Japanese patients. Anticancer Drugs 2003; 14:801–7.
Haddad R, Tishler RB, Norris CM, Mahadevan A, Busse P, Wirth L, et al. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist 2003; 8:35–44.
List MA, D'Antonio LL, Cella DF, Siston A, Mumby P, Haraf D, Vokes E. The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale: A study of utility and validity. Cancer 1996; 77:2294–2301.
Okura M, Hiranuma T, Adachi T, Ogura T, Aikawa T, Yoshioka H, et al. Induction chemotherapy is Associated with an increase in the incidence of locoregional recurrence in patients with carcinoma of the oral cavity. Cancer 1998; 82:804–15.
Licitra L, Grandi C, Guzzo M, Mariani L, Lo Vullo S, Valvo F, et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: A randomized controlled trial. J Clin Oncol 2003; 21:327–33.
Schuller DE, Metch B, Stein DW, Mattox D, McCracken JD. Preoperative chemotherapy in advanced resectable head and neck cancer: Final report of the Southwest Oncology Group. Laryngoscope 1988; 98:1205–11.

Date Created: 20240718 Date Completed: 20240718 Latest Revision: 20240718

20240718

10.4103/jcrt.jcrt_172_22

39023578